IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 7.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 346,765 shares of the company's stock after selling 29,588 shares during the period. Dimensional Fund Advisors LP owned 0.40% of IDEAYA Biosciences worth $8,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC increased its holdings in shares of IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after purchasing an additional 327,498 shares in the last quarter. Vanguard Group Inc. increased its position in IDEAYA Biosciences by 5.9% in the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after acquiring an additional 282,936 shares during the period. Geode Capital Management LLC lifted its holdings in shares of IDEAYA Biosciences by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after purchasing an additional 43,226 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in shares of IDEAYA Biosciences by 2.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company's stock valued at $49,891,000 after buying an additional 46,931 shares during the period. Finally, Candriam S.C.A. raised its position in shares of IDEAYA Biosciences by 14.0% in the 4th quarter. Candriam S.C.A. now owns 1,071,825 shares of the company's stock valued at $27,546,000 after purchasing an additional 131,385 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Performance

Shares of IDYA traded down $0.90 during midday trading on Tuesday, hitting $17.45. 862,899 shares of the stock traded hands, compared to its average volume of 993,549. The firm has a market capitalization of $1.53 billion, a PE ratio of -5.29 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42. The business's 50 day moving average price is $17.72 and its two-hundred day moving average price is $22.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the company posted ($0.53) earnings per share. As a group, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on IDYA shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Stephens reissued an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.